Artwork by participants in the Studio E: The Epilepsy Art Therapy Program was on display at the annual meeting of the American Epilepsy Society. Overwhelmingly positive feedback for the Studio E program has inspired upcoming research to further understand the potential benefits of art therapy for people with epilepsy.
This is the second year that Lundbeck and the Epilepsy Foundation have joined forces to support this important program. “Through the creative process, art therapy provides people a non-verbal way to identify, communicate and work towards resolving conflicts and problems, and consequently to reduce stress, increase self-esteem and restore an internal locus of control,” said Dr. Steven Schachter, professor of neurology, Harvard Medical School and chief academic officer, Center for Integration of Medicine and Innovative Technology.
The Studio E program offers weekly group art therapy sessions for adults, teens and children living with epilepsy. The participants work with licensed art therapists using a variety of artistic media, including painting, sketching and sculpting over several sessions.
For more information:
www.yourpartnerinepilepsy.com
(312) 233.1356
maggie.dimatteo@edelman.com
Jessica Keenan Smith is a patient advocate and epilepsy community leader with more than 15 years of experience. As Founder and CEO of Living Well With Epilepsy and Executive Director of ASENT she bridges the gap between the scientific and patient communities, with a particular focus on the needs of the epilepsies. Jessica Keenan Smith is Founder and CEO of Living Well With Epilepsy, an award winning online resource for people affected by epilepsy to share stories and access in-depth information on the disease. Since 2009, Living Well With Epilepsy (https://livingwellwithepilepsy.com) has been featured in Forbes, Wired, NBC, NPR and the cover story of Epilepsy Advocate Magazine and has partnered with companies such as UCB, Lundbeck, Sunovion, Eisai, and more. Ms. Smith is also the Executive Director of the American Society for Experimental Neurotherapeutics (ASENT) (https://asent.org), an organization that brings together leaders from industry, academia, government and advocacy who are engaged in bringing drugs and devices to market across all neurologic disease states. In this role she is responsible for leading a successful scientific journal and annual scientific conference with speakers from all over the world.
Leave a Reply